Aripiprazole depot 300 or 400 mg

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Drug Information

Target Indication

Schizophrenia

Clinical Trial

Last updated: 12/17/2025

Regulatory Approvals

EMAPending

Abilify MyCite

Treatment of schizophrenia, or of moderate to severe manic episodes in bipolar I disorder with sensor to measure medication adherence

EMAPending

Asimtufii

Maintenance treatment of schizophrenia.

EMA11/14/2013

Abilify Maintena

Maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole.

Developer

OTSKF

OTSUKA

Related Pipeline

Hyperlipidemia

Attention Deficit Hyperactivity Disorder (ADHD)

Phenylketonuria (PKU)

Attention Deficit/Hyperactivity Disorder

Attention-Deficit/Hyperactivity Disorder